

AGENDA

Mayflower Renaissance Hotel, 1127 Connecticut Avenue NW

Wednesday, February 26th

4:00-8:00 pm Registration open.....Grand Ballroom Promenade

6:30-8:30 pm **Welcome Reception: "A Celebration of Progress for Patients"****State Room**

Thursday, February 27th

7:00 am-5:00 pm Registration open.....Grand Ballroom Promenade

7:00-8:15 am General Breakfast.....State Room

7:00-8:15 am Young Investigators Breakfast (by invitation only).....Senate Room
"The successful mid-career transition: a conversation"

8:30-8:45 Opening Remarks.....**Grand Ballroom**

Wendy Selig, MRA President and Chief Executive Officer
Louise Perkins, MRA Chief Science Officer

**8:45-10:05 Intersection of Immunotherapeutics and Kinase Inhibitors:
Current Treatments and Emerging Paradigms**
Chair: Michael Atkins

8:45-9:10 Jedd Wolchok, Memorial Sloan-Kettering Cancer Center: Checkpoint blockade
combination therapy

9:10-9:30 Neal Rosen, Memorial Sloan-Kettering Cancer Center: Combinatorial approaches to treating
mutant BRAF melanomas

9:30-9:50 Mary Jo Turk, Dartmouth College: BRAF-inhibition and tumor immune-suppression: lessons from
a mouse model

9:50-10:05 Michael Atkins, Georgetown Lombardi Cancer Center: Kinetics and effects of BRAF inhibitors on
intratumoral immunity

10:05-10:20 *BREAK*

10:20-11:45 pm Biomarkers: The Key to Melanoma Prognosis and Treatment Outcomes
Chair: Suzanne Topalian

10:20-10:45 Meenhard Herlyn, Wistar Institute: Drivers in melanoma development and progression

10:45-11:05 Graeme Walker, Queensland Institute for Medical Research: Discovery of genes for melanoma
development using the Collaborative Cross approach

11:05-11:25 Jeffrey Trent, Translational Genomics Research Institute (TGen): Personalized medicine for BRAF
wild type melanoma

11:25-11:45 Suzanne Topalian, Johns Hopkins University: PD-1 pathway blockade: markers of response and
mechanisms of resistance

Thursday, February 27th (cont.)

- 11:45-12:15 Special Lecture:** Stephen Baylin, Johns Hopkins University.....**Grand Ballroom**
Can Epigenetic Therapy Sensitize to Checkpoint Immunotherapy?
- 12:30-1:45 pm Lunch and Discussion**.....**State Room**
- Connie Mack, Senior Policy Advisor, Liberty Partners Group LLC; Former U.S. Senator; and MRA Board Member
 - Michael Milken, Chairman, the Milken Institute and MRA Board Member
 - Cokie Roberts, Political commentator, NPR and ABC
- 2:00-3:20 pm Therapeutic Targeting of NRAS Mutant Melanoma**.....**Grand Ballroom**
Chair: Levi Garraway
- 2:00-2:20 Douglas Faller, Boston University: Targeting NRAS as a therapeutic approach for melanoma
- 2:20-2:40 Xu Wu, Massachusetts General Hospital: Targeting NRAS palmitoylation in melanoma
- 2:40-3:00 Susana Ortiz-Urda, University of California, San Francisco: Mechanisms of resistance for constitutively-activated NRAS melanoma
- 3:00-3:20 Levi Garraway, Dana-Farber Cancer Institute: The development of rational therapeutic regimens for NRAS-mutant melanoma
- 3:20-3:35 *BREAK*
- 3:35-4:55 pm Combination Therapies for Melanoma**
Chair: Charles Drake
- 3:35-3:55 Kai Wucherpfennig, Dana-Farber Cancer Institute: Synergistic targeting of inhibitory T cell pathways in melanoma
- 3:55-4:15 Ramesh Rengan, Fred Hutchinson Cancer Research Center: RADVAX: Stereotactic body radiation therapy with ipilimumab in melanoma
- 4:15-4:35 Fan Pan, Johns Hopkins University: Targeting HIF-1 inhibitors in combination with Treg depleting drugs (cyclophosphamide) and targeted anti-melanoma therapy
- 4:35-4:55 Charles Drake, Johns Hopkins University: Combination therapy to augment anti-PD-1 in melanoma
- 4:55 pm Closing Remarks:** Laura Brockway-Lunardi, MRA Scientific Program Director
- 6:30-10:00 pm Reception and Dinner**.....**Hill Country Barbecue**
Dress: Casual
410 7th Street NW, (202) 556-2050
6:15-7:15 pm, Transportation provided to restaurant, Pick up at Desales Street entrance of hotel
6:30-7:30 Reception; 7:30 Dinner; 8:30 Line Dancing

Friday, February 28th

- 7:00-10:00 am Registration open.....Grand Ballroom Promenade
- 7:00-8:30 am General Breakfast.....State Room
- 7:00-8:30 am Industry Roundtable Breakfast (by invitation only).....Colonial Room
"Development of adjuvant and neo-adjuvant therapies for melanoma and other cancers"
- 8:40-8:45 am Opening Remarks Day 2: Louise Perkins, MRA Chief Science Officer**
- 8:45-11:10 New Strategies for Target Discovery and Credentialing.....Grand Ballroom**
Chair: Glenn Dranoff
- 8:45-9:05 Jonathan Cebon, Ludwig Institute for Cancer Research, Melbourne-Austin Branch: Targeting inducible invasive cells in melanoma
- 9:05-9:25 Barbara Bedogni, Case Western Reserve University: Targeting melanocyte precursor pathways for melanoma therapy
- 9:25-9:50 Christopher Vakoc, Cold Spring Harbor Laboratory: A functional approach to targeted melanoma therapy
- 9:50-10:10 Chris Sander, Memorial Sloan-Kettering Cancer Center: Network models of signaling pathways and combinatorial therapy in melanoma
- 10:10-10:25 *BREAK*
- 10:25-10:45 Jeffrey Ravetch, Rockefeller University: Enhancing immunotherapeutic activity of agonistic anti-CD-40 antibodies
- 10:45-11:10 Glenn Dranoff, Dana Farber Cancer Institute: Human anti-MICA monoclonal antibodies for melanoma immunotherapy
- 11:10-12:10 Selected Therapeutic Approaches: Unanswered Questions, Future Roles**
Chair: Paul Chapman, Memorial Sloan-Kettering Cancer Center
- 11:10-11:30 Surgery: Daniel Coit, Memorial Sloan-Kettering Cancer Center
- 11:30-11:50 Vaccines: Nina Bhardwaj, Icahn School of Medicine at Mount Sinai
- 11:50-12:10 Adoptive cell therapy: Steven Rosenberg, U.S. National Cancer Institute
- 12:10 pm Closing Remarks: Louise Perkins**
- 12:15-1:30 pm General Lunch.....State Room